Success Metrics

Clinical Success Rate
95.0%

Based on 19 completed trials

Completion Rate
95%(19/20)
Active Trials
0(0%)
Results Posted
21%(4 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_3
5
25%
Ph phase_4
5
25%
Ph phase_1
3
15%
Ph early_phase_1
1
5%
Ph not_applicable
2
10%
Ph phase_2
4
20%

Phase Distribution

4

Early Stage

4

Mid Stage

10

Late Stage

Phase Distribution20 total trials
Early Phase 1First-in-human
1(5.0%)
Phase 1Safety & dosage
3(15.0%)
Phase 2Efficacy & side effects
4(20.0%)
Phase 3Large-scale testing
5(25.0%)
Phase 4Post-market surveillance
5(25.0%)
N/ANon-phased studies
2(10.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

95.0%

19 of 20 finished

Non-Completion Rate

5.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

20

all time

Status Distribution
Completed(19)
Terminated(1)

Detailed Status

Completed19
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
20
Active
0
Success Rate
95.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (5.0%)
Phase 13 (15.0%)
Phase 24 (20.0%)
Phase 35 (25.0%)
Phase 45 (25.0%)
N/A2 (10.0%)

Trials by Status

completed1995%
terminated15%

Recent Activity

Clinical Trials (20)

Showing 20 of 20 trials
NCT00120367Phase 2

Early Intensification of Antiretroviral Therapy Including Enfuvirtide in HIV-1-Related Progressive Multifocal Leucoencephalopathy (ANRS125)

Completed
NCT01836068Early Phase 1

Optimized Antiretroviral Therapy During Allogeneic Hematopoietic Stem Cell Transplantation in HIV-1 Individuals

Completed
NCT00537394Phase 3

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

Completed
NCT00051831Not Applicable

Effect of an Enfuvirtide-based Anti-HIV Drug Regimen on Latent HIV Reservoirs in Treatment Naive Adults

Completed
NCT00031044Phase 1

Adding New Drugs for HIV Infected Patients Failing Current Therapy

Completed
NCT00001118Phase 1

Study of a New Anti-HIV Drug, T-20, in HIV-Infected Children

Completed
NCT00344760Phase 4

A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy

Completed
NCT02569502Phase 4

A Study of Enfuvirtide (Fuzeon) in Patients With Advanced Human Immunodeficiency Virus-1 (HIV-1) Infection

Completed
NCT02582983Phase 4

A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection

Completed
NCT02733419Phase 3

Efficacy, and Safety Study of Optimized Background Antiretroviral Regimen (OB) in Combination With Enfuvirtide in the Treatment-Experienced Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection

Completed
NCT00022763Phase 2

T-20 Plus a Selected Anti-HIV Treatment in HIV-Infected Children and Adolescents

Completed
NCT00487188Phase 4

A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience

Completed
NCT00302822Phase 3

Intensification With Enfuvirtide in Naive HIV-infected Patients (ANRS130)

Completed
NCT00334022Not Applicable

Fuzeon Viral Decay Pilot Study

Completed
NCT00312546Phase 1

Study of Valproic Acid to Treat HIV Infected Adults

Terminated
NCT00657761Phase 4

Metabolic Effects of Enfuvirtide in Healthy Volunteers

Completed
NCT00002239Phase 2

A Study to Compare Three Doses of T-20 When Given in Combination With Abacavir, Amprenavir, Ritonavir, and Efavirenz to HIV-Infected Adults

Completed
NCT00021554Phase 3

T-20 in HIV Patients With Prior Drug Treatment and/or Resistance to Each of the Three Classes of Anti-HIV Drugs

Completed
NCT00002228Phase 2

A Study of T-20 in HIV-Positive Adults

Completed
NCT00008528Phase 3

T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs

Completed

All 20 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
20